Adolescent depression and suicide are on the rise, yet effective care is limited by long waitlists and large out-of-pocket costs for therapy, limited pharmacological options, and stigma surrounding mental health.
SparkRx is available now under the FDA’s policy to treat psychiatric disorders during COVID-19.
Limbix is creating prescription digital therapeutics (PDTs) to enable doctors to prescribe digital, evidence-based, therapeutic interventions for adolescent mental health.
PDTs require strict compliance with FDA quality management standards and are validated through rigorous clinical trials. Upon FDA clearance, PDTs can be prescribed by a doctor to treat specific medical conditions.
Limbix creates digital therapeutics with significant input from teenagers who provide us valuable feedback. If you are a teen interested in helping Limbix design thoughtful digital experiences for current and future generations of young people, email email@example.com!Learn More
Limbix relies on clinical experts who provide critical product feedback to help ensure the digital therapeutics we create are evidence-based and beneficial for patients. If you are a physician looking to connect with Limbix to provide your input, please join our Physician Advisory Group.Join Physician Advisory Group